News | Lung Imaging | August 02, 2021

SIR considers image-guided thermal ablation to be an acceptable treatment option for patients with inoperable Stage I NSCLC, those with recurrent NSCLC, as well as patients with metastatic lung disease

SIR considers image-guided thermal ablation to be an acceptable treatment option for patients with inoperable Stage I NSCLC, those with recurrent NSCLC, as well as patients with metastatic lung disease

Getty Images


August 2, 2021 — The Society of Interventional Radiology (SIR) issued a new position statement on percutaneous lung ablation. The position statement was published in the August issue of the Journal of Vascular and Interventional Radiology (JVIR) with an accompanying quality improvement document, which establishes performance thresholds for patient safety.

“Minimally invasive, image-guided thermal ablation offers patients with early stage, non-small-cell lung cancer, recurring lung cancer, and metastatic disease a safe and effective treatment option,” said Mark Baerlocher, M.D., SIR’s standards division councilor and an author of the position statement and quality improvement document.

“The two publications provide physicians with guidance on everything from patient selection to treatment delivery and post-treatment care and follow-up, ensuring high-quality care that improves patients’ lives,” said Baerlocher, an interventional radiologist at the Royal Victoria Hospital, Ontario, Canada.

Lung cancer is the second most common newly diagnosed cancer in the United States, with an estimated 228,000 new cases diagnosed in 2020. It is also the leading cause of cancer-related death.

Interventional radiologists use image-guided thermal ablation to treat primary and secondary lung tumors. Based on the current evidence, the position statement recommends that radiofrequency ablation, cryoablation and microwave ablation are all appropriate forms of image-guided thermal ablation to treat these tumors. The method of ablation should be determined by lesion characteristics and risk mitigation, according to the new document.

“Evidence-based position statements are important means of improving patient outcomes,” said SIR President Mathew S. Johnson, M.D., FSIR, the Gary J. Becker Professor of Radiology Research at Indiana University School of Medicine in Indianapolis. “Future comparative studies on the use of thermal ablation to treat these forms of lung cancer will help improve the evidence base and allow us to make stronger recommendations to the benefit of patients.”

The position statement was developed by a multidisciplinary group of authors including interventional radiology, medical oncology, thoracic surgery and radiation oncology specialists. It is endorsed by the Canadian Association for Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe and the Society of Interventional Oncology.

Read the full position statement and quality improvement document on jvir.org.


Related Content

News | Mammography

April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution ...

Time April 12, 2024
arrow
News | Mammography

April 12, 2024 — GE HealthCare, a leader in breast health technology and diagnostics, will feature its latest breast ...

Time April 12, 2024
arrow
News | Radiation Therapy

April 12, 2024 — RTsafe, a leading provider of quality assurance products and services in stereotactic radiosurgery, and ...

Time April 12, 2024
arrow
News | Artificial Intelligence

April 9, 2024 —PreciseDx, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for ...

Time April 09, 2024
arrow
News | Artificial Intelligence

April 8, 2024 — Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today ...

Time April 08, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Here is a snapshot of the Top 10 most-read content from ITN's viewers during the month of March: 1. Philips Teams with ...

Time April 04, 2024
arrow
News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Radiation Therapy

March 28, 2024 — RefleXion Medical, Inc., a therapeutic oncology company, and Limbus AI, Inc., a provider of software ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
News | Artificial Intelligence

March 21, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time March 21, 2024
arrow
Subscribe Now